# Human PARP-1 / PARP Protein (His Tag)

Catalog Number: 11040-H08B



### **General Information**

### Gene Name Synonym:

ADPRT; ADPRT1; ARTD1; pADPRT-1; PARP; PARP-1; PPOL

### **Protein Construction:**

The amino acids corresponding to the full length of human PARP1 (NP\_001609.2) (Met 1-Trp 1014) was fused with a polyhistidine tag at the C-terminus

Source: Human

**Expression Host:** Baculovirus-Insect Cells

**QC** Testing

Purity: > 90 % as determined by SDS-PAGE

**Endotoxin:** 

< 1.0 EU per  $\mu g$  of the protein as determined by the LAL method

Predicted N terminal: Met

### **Molecular Mass:**

The recombinant human PARP1 consists of 1024 amino acids and predicts a molecular mass of 114.5 kDa. The apparent molecular mass of rhPARP1 is approximately 100-110 kDa in SDS-PAGE under reducing conditions.

### Formulation:

Supplied as sterile 20 mM Tris, 300 mM NaCl, 10 % glycerol, 0.5 mM TCEP, 2 mM EDTA, pH 7.5.

# **Usage Guide**

# Stability & Storage:

Samples are stable for twelve months from date of receipt at -20°C to -80°C.


Store it under sterile conditions at -20°C to -80°C upon receiving. Recommend to aliquot the protein into smaller quantities for optimal storage.

Avoid repeated freeze-thaw cycles.

## Reconstitution:

Detailed reconstitution instructions are sent along with the products.

#### SDS-PAGE:



# **Protein Description**

Poly (ADP-ribose) polymerase 1(PRAP1), also known as NAD(+) ADPribosyltransferase 1(ADPRT), is a chromatin-associated enzyme which modifies various nuclear proteins by poly(ADP-ribosyl)ation. The ADP-Dribosyl group of NAD+ is transferred to an acceptor carboxyl group on a histone or the enzyme itself, and further ADP-ribosyl groups are transferred to the 2'-position of the terminal adenosine moiety, building up a polymer with an average chain length of 2-3 units. The poly(ADPribosyl)ation modification is critical for a wide range of processes, including DNA repair, regulation of chromosome structure, transcriptional regulation, mitosis and apoptosis. PARP1 is demonstrateed to mediate the poly(ADP-ribose) ation of APLF (aprataxin PNK-like factor) and CHFR (checkpoint protein with FHA and RING domains), two representative proteins involved in the DNA damage response and checkpoint regulation. Further, It has been suggested that DNA-dependent protein kinase (DNA-PK), another component of DNA repair, suppresses PARP activity, probably through direct binding and/or sequestration of DNA-ends which serve as an important stimulator for both enzymes. PARP1 inhibitors is thus proposed as a targeted cancer therapy for recombination deficient cancers, such as BRCA2 tumors.

#### References

Malanga M. et al., 1998, J Biol Chem. 273: 11839-11843.
Ariumi Y. et al., 1999, Oncogene. 18: 4616-4625.
Helleday T. et al., 2005, Cell Cycle. 4: 1176-1178.